Differences in the use of combined oral contraceptives amongst women with and without acne

H E Seaman, Corinne S de Vries, R D T Farmer

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) provides a treatment option for women with acne, hirsutism or polycystic ovary syndrome (PCOS). CPA/EE may be prescribed as an oral contraceptive (OC), but is not licensed as such in the UK. The use of CPA/EE steadily increased after its introduction to the UK market in 1987, but there was a marked increase in its share of the OC market after 1995.

METHODS: Using the General Practice Research Database, utilization patterns of CPA/EE and conventional oral contraceptives were compared in women aged 15-39 years, with or without acne or PCOS.

RESULTS: Between 1994 and 1998, CPA/EE accounted for an increasing proportion of all OC use. The proportion of CPA/EE prescribed to women with acne declined between 1994 and 1998, whereas that prescribed to women with PCOS remained constant. The age-specific use of CPA/EE by women with acne or PCOS almost doubled. After 1995, there was a marked increase in the use of products containing levonorgestrel by women with acne or PCOS.

CONCLUSIONS: A large proportion of CPA/EE is prescribed to women with acne and/or PCOS, although this proportion decreased between 1992 and 1998. This has important implications in CPA/EE risk assessment studies.

Original languageEnglish
Pages (from-to)515-521
Number of pages7
JournalHuman Reproduction
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Contraceptives, Oral, Combined
Cyproterone Acetate
Ethinyl Estradiol
Acne Vulgaris
Polycystic Ovary Syndrome
Oral Contraceptives
Hirsutism
Levonorgestrel
General Practice
Databases

Cite this

Differences in the use of combined oral contraceptives amongst women with and without acne. / Seaman, H E; de Vries, Corinne S; Farmer, R D T.

In: Human Reproduction, Vol. 18, No. 3, 03.2003, p. 515-521.

Research output: Contribution to journalArticle

Seaman, H E ; de Vries, Corinne S ; Farmer, R D T. / Differences in the use of combined oral contraceptives amongst women with and without acne. In: Human Reproduction. 2003 ; Vol. 18, No. 3. pp. 515-521.
@article{f022bbff5da549eaa054c1a834d64be6,
title = "Differences in the use of combined oral contraceptives amongst women with and without acne",
abstract = "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) provides a treatment option for women with acne, hirsutism or polycystic ovary syndrome (PCOS). CPA/EE may be prescribed as an oral contraceptive (OC), but is not licensed as such in the UK. The use of CPA/EE steadily increased after its introduction to the UK market in 1987, but there was a marked increase in its share of the OC market after 1995. METHODS: Using the General Practice Research Database, utilization patterns of CPA/EE and conventional oral contraceptives were compared in women aged 15-39 years, with or without acne or PCOS. RESULTS: Between 1994 and 1998, CPA/EE accounted for an increasing proportion of all OC use. The proportion of CPA/EE prescribed to women with acne declined between 1994 and 1998, whereas that prescribed to women with PCOS remained constant. The age-specific use of CPA/EE by women with acne or PCOS almost doubled. After 1995, there was a marked increase in the use of products containing levonorgestrel by women with acne or PCOS. CONCLUSIONS: A large proportion of CPA/EE is prescribed to women with acne and/or PCOS, although this proportion decreased between 1992 and 1998. This has important implications in CPA/EE risk assessment studies.",
author = "Seaman, {H E} and {de Vries}, {Corinne S} and Farmer, {R D T}",
year = "2003",
month = "3",
doi = "10.1093/humrep/deg090",
language = "English",
volume = "18",
pages = "515--521",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Differences in the use of combined oral contraceptives amongst women with and without acne

AU - Seaman, H E

AU - de Vries, Corinne S

AU - Farmer, R D T

PY - 2003/3

Y1 - 2003/3

N2 - BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) provides a treatment option for women with acne, hirsutism or polycystic ovary syndrome (PCOS). CPA/EE may be prescribed as an oral contraceptive (OC), but is not licensed as such in the UK. The use of CPA/EE steadily increased after its introduction to the UK market in 1987, but there was a marked increase in its share of the OC market after 1995. METHODS: Using the General Practice Research Database, utilization patterns of CPA/EE and conventional oral contraceptives were compared in women aged 15-39 years, with or without acne or PCOS. RESULTS: Between 1994 and 1998, CPA/EE accounted for an increasing proportion of all OC use. The proportion of CPA/EE prescribed to women with acne declined between 1994 and 1998, whereas that prescribed to women with PCOS remained constant. The age-specific use of CPA/EE by women with acne or PCOS almost doubled. After 1995, there was a marked increase in the use of products containing levonorgestrel by women with acne or PCOS. CONCLUSIONS: A large proportion of CPA/EE is prescribed to women with acne and/or PCOS, although this proportion decreased between 1992 and 1998. This has important implications in CPA/EE risk assessment studies.

AB - BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) provides a treatment option for women with acne, hirsutism or polycystic ovary syndrome (PCOS). CPA/EE may be prescribed as an oral contraceptive (OC), but is not licensed as such in the UK. The use of CPA/EE steadily increased after its introduction to the UK market in 1987, but there was a marked increase in its share of the OC market after 1995. METHODS: Using the General Practice Research Database, utilization patterns of CPA/EE and conventional oral contraceptives were compared in women aged 15-39 years, with or without acne or PCOS. RESULTS: Between 1994 and 1998, CPA/EE accounted for an increasing proportion of all OC use. The proportion of CPA/EE prescribed to women with acne declined between 1994 and 1998, whereas that prescribed to women with PCOS remained constant. The age-specific use of CPA/EE by women with acne or PCOS almost doubled. After 1995, there was a marked increase in the use of products containing levonorgestrel by women with acne or PCOS. CONCLUSIONS: A large proportion of CPA/EE is prescribed to women with acne and/or PCOS, although this proportion decreased between 1992 and 1998. This has important implications in CPA/EE risk assessment studies.

UR - http://dx.doi.org/10.1093/humrep/deg090

U2 - 10.1093/humrep/deg090

DO - 10.1093/humrep/deg090

M3 - Article

VL - 18

SP - 515

EP - 521

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 3

ER -